BioLineRx licenses BL-5010 to Innovative Pharmaceutical
Jerusalem, Israel-based BioLineRx, a clinical-stage drug development firm, has signed a worldwide exclusive license agreement with privately-held Innovative Pharmaceutical Concepts for the development and commercialization of BL-5010, a novel formulation for the non-surgical removal of skin lesions. Financial terms of the deal were not disclosed.
According to BioLineRx, BL-5010 is a convenient treatment that offers an alternative to painful, invasive and expensive removal treatments such as surgery, cryotherapy or laser treatment. Because it is non-invasive, it poses minimal infection risk and no need for anesthesia or bandaging, the firm noted.
The product is applied topically onto the lesion for a few minutes, causing it to gradually dry out and shed from the skin within one-three weeks. BL-5010 also preserves the cellular structure of the lesion, enabling histological examination.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze